Global Biocontrol Commercialization

Micropep Files First Regulatory Submissions for Promisin™, a Novel Peptide Biofungicide with a New Mode of Action

Brazil and Paraguay Dossiers Launch Global Commercial Rollout of Crop Protection Micropeptides

In a landmark operational transition from laboratory discovery to global commercialization, Micropep Files First Regulatory Submissions for Promisin™, a Novel Peptide Biofungicide with a New Mode of Action. Announced on June 23, 2026, the initial regulatory filings in Brazil and Paraguay kick off a multi-region strategy, with subsequent dossiers prepared for submission in the United States and European Union. Discovered via the firm’s AI-driven Krisalix™ screening engine, Promisin™ introduces a novel biological mode of action that targets and breaks down fungal cell membranes to combat resistant row-crop diseases, including Asian Soybean Rust and Target Spot. Backed by more than 200 rigorous global field validation trials, the peptide molecule provides standalone protection while maintaining a low-cost manufacturing profile designed to ease standard row-crop adoption barriers.

RALEIGH, NC & TOULOUSE, FRANCE — June 23, 2026 — Micropep Technologies today announced the submission of regulatory dossiers for Promisin™, its lead peptide-based biofungicide, in Brazil and Paraguay. The filings mark a key milestone as the company moves from development to commercialization, with additional submissions planned in the United States and European Union.

Promisin is a broad-spectrum crop protection solution designed to control major fungal diseases while fitting seamlessly into existing farming systems. It introduces a new active ingredient, featuring a novel biological mode of action as an antimicrobial peptide, developed for both performance and scalability. In addition, Promisin has been built for row crop use, with a focus not only on efficacy but also on delivering a cost profile that works for growers.

The submissions are supported by more than three years of development and an extensive global field program, including over 200 trials, conducted under high disease pressure across Europe, North America, and South America. In these trials, Promisin demonstrated consistent efficacy as a standalone solution and enhanced performance when integrated into standard crop protection programs.

“There’s a clear need for new solutions as resistance pressure builds and regulatory expectations evolve,” said Dr. Kevin Leiner, VP of Regulatory Affairs at Micropep. “Promisin delivers a highly favorable efficacy, safety, and sustainability profile that represents the forefront of a coming wave of peptide-based biocontrol products for agriculture. These first submissions are an important step toward making that available to growers at scale.”

A New Defense Against Resistant Soybean Fungal Diseases

Fungal diseases continue to put significant pressure on global agriculture, while many conventional fungicides face declining effectiveness or increasing regulatory constraints. Promisin addresses this challenge with a novel peptide-based approach designed to deliver:

• Broad-Spectrum Suppression: Control of key fungal diseases in soybeans, including Phakopsora pachyrhizi (Asian Soybean Rust), Corynespora cassiicola (Target Spot), and Cercospora kikuchii (Leaf Blight).
• Integrated Performance: Effective standalone disease control and enhanced synergy when integrated into combination tank mixes and standard spray programs.
• Resistance Management: A novel biological mode of action that systematically disrupts fungal cell membranes, weakening infection pressure.
• Row Crop Economics: An affordable cost structure aligned with extensive crop budgets, resolving a major pricing barrier that slowed earlier bio-input adoptions.

“Promisin represents what we set out to build from day one: a peptide-based crop protection solution that delivers efficacy at a cost structure that works for row crops,” said Georg Goeres, Chief Executive Officer of Micropep. “Growers need products that perform, fit into their operations, and make economic sense. With Promisin, we’re delivering on all three.”

Promisin is the first commercial molecule to emerge from Micropep’s proprietary Krisalix™ platform, which utilizes generative AI and predictive modeling to discover next-generation peptide structures. The company is currently advancing a broader research pipeline of over ten peptide candidates designed to target invasive weeds, plant pathogens, and insect pests.

About Micropep Technologies

Micropep Technologies is a prominent French-American biotechnology company developing a new category of targeted, sustainable crop protection products using naturally derived micropeptides. Through its integrated computational platform Krisalix™, Micropep designs short protein structures that safely regulate specific biological interactions, helping global farmers secure maximum yields without expanding the chemical footprint.

Micropep Technologies — Corporate Press & Regulatory Registry

Raleigh, NC & Toulouse, France | International Regulatory Filing Briefing | June 2026 | micro-pep.com